These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. The use of systemic immunity adjuvants in the prophylaxis or therapy of cancer. Mathé G; Halle-Pannenko O; Bourut C; Hiu IJ Johns Hopkins Med J Suppl; 1974; 3():85-102. PubMed ID: 4154074 [No Abstract] [Full Text] [Related]
4. Activated macrophages and the antitumor action of BCG. Alexander P Natl Cancer Inst Monogr; 1973 Dec; 39():127-33. PubMed ID: 4595313 [No Abstract] [Full Text] [Related]
5. [Immunotherapy of cancer with BCG]. Yamamura Y; Azuma I Nihon Rinsho; 1974 Mar; 32(3):542-53. PubMed ID: 4603604 [No Abstract] [Full Text] [Related]
6. Cancer immunotherapy. Richman SP; Gutterman JU; Hersh EM Can Med Assoc J; 1979 Feb; 120(3):322-4, 329. PubMed ID: 371776 [TBL] [Abstract][Full Text] [Related]
7. Experimental and clinical trials with BCG immunotherapy. Sparks FC; Silverstein MJ; Hunt JS; O'Connell TX; Lee YT; Pilch YH; Haskell CM; Morton DL Johns Hopkins Med J Suppl; 1974; 3():103-20. PubMed ID: 4609024 [No Abstract] [Full Text] [Related]
10. BCG as adjuvant immunotherapy for neoplasia. Hersh EM; Gutterman JU; Mavligit GM Annu Rev Med; 1977; 28():489-515. PubMed ID: 324372 [No Abstract] [Full Text] [Related]
11. Immunological adjuvants in cancer immunotherapy. Baldwin RW Dev Biol Stand; 1977 Apr 13-15; 38():3-12. PubMed ID: 344097 [No Abstract] [Full Text] [Related]
12. [A review on mechanism of anti-tumor action of BCG (author's transl)]. Tokunaga T Kekkaku; 1980 Aug; 55(8):351-7. PubMed ID: 6999202 [No Abstract] [Full Text] [Related]
13. Immunotherapy of guinea pig cancer with BCG. Zbar B Johns Hopkins Med J Suppl; 1974; 3():121-30. PubMed ID: 4608693 [No Abstract] [Full Text] [Related]
14. Cancer active immunotherapy. Immunoprophylaxis and immunorestoration. An introduction. Mathé G Recent Results Cancer Res; 1976; 55():1-402. PubMed ID: 1087040 [No Abstract] [Full Text] [Related]
15. Immunological parameters of host-tumor relationships. V. Introduction: Tumor immunology and immunotherapy in 1977. Weiss DW Isr J Med Sci; 1978 Jan; 14(1):1-13. PubMed ID: 305432 [No Abstract] [Full Text] [Related]
16. Mechanism of Bacillus Calmette-Guérin-induced suppression of metastases in a poorly immunogenic fibrosarcoma. Liotta LA; Kleinerman J; Saidel GM Cancer Res; 1976 Sep; 36(9 pt.1):3255-9. PubMed ID: 788897 [TBL] [Abstract][Full Text] [Related]
17. Nonspecific antigen reactions. Klein E; Rosner D; Holtermann OA; Stoll HL; Song SY Natl Cancer Inst Monogr; 1976 Nov; 44():87-97. PubMed ID: 799764 [TBL] [Abstract][Full Text] [Related]
18. A comparison of in vitro cell-mediated reactivity against syngeneic tumor cells by various lymphoid cell populations from Bacillus Calmette-Guérin-tumor-cured, tumor-sensitized, tumor-bearing, and normal inbred guinea pigs. Fidler IJ; Kataoka T; Hanna MG Cancer Res; 1976 Dec; 36(12):4459-66. PubMed ID: 187324 [TBL] [Abstract][Full Text] [Related]
19. Immunotherapy of cancer with cell wall skeleton of Myocabacterium bovis-Bacillus Calmette-Guérin: experimental and clinical results. Yamamura Y; Azuma I; Taniyama T; Sugimura K; Hirao F; Tokuzen R; Okabe M; Nakahara W; Yasumoto K; Ohta M Ann N Y Acad Sci; 1976; 277(00):209-27. PubMed ID: 826205 [TBL] [Abstract][Full Text] [Related]
20. Bacillus Calmette-Guérin immunotherapy in combination with DTIC (NSC-45388) for the treatment of malignant melanoma. Gutterman JU; Mavligit GM; Reed R; Burgess MA; Gottlieb J; Hersh EM Cancer Treat Rep; 1976 Feb; 60(2):177-82. PubMed ID: 769970 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]